Patents by Inventor STina Gestrelius
STina Gestrelius has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110312891Abstract: Isolated active compound of a naturally occurring fraction of Enamel Matrix Derivatives (EMD), having at least one of each two N-terminal polypeptide fragments of amelogenin, which are at least 95% identical to an amino acid sequence as shown in SEQ. ID. No:1 and/or 2. The invention relates to the use of said isolated active compound of a fraction and/or of the fraction itself, and/or the at least one of each two polypeptide fragments for use as a medicament and/or for the manufacture of a pharmaceutical composition for a variety of different medical indications such as inducing and/or promoting cementogenesis, bone growth and/or binding between parts of living mineralised tissue, for bonding of a piece of living mineralised tissue to a bonding site on a piece of other living tissue, for endorsing binding between hard tissues, for inducing regeneration of dentin, and/or for filling a mineralized wound cavity and/or tissue defect following from a procedure and/or trauma.Type: ApplicationFiled: June 29, 2009Publication date: December 22, 2011Applicant: Straumann Holding AGInventors: Stina Gestrelius, Michel Dard, Ruzica Ranevski, S. Petter Lyngstadaas, Corinna Mauth
-
Patent number: 7960347Abstract: Enamel matrix, enamel matrix derivatives and/or enamel matrix proteins or peptides may be used as therapeutic or prophylactic agents for inducing programmed cell death (apoptosis), in particular in the treatment or prevention of cancer or malignant or benign neoplasms.Type: GrantFiled: April 14, 2010Date of Patent: June 14, 2011Assignee: Institut Straumann AGInventors: Lars Hammarstrom, Stale Petter Lyngstadaas, Stina Gestrelius
-
Patent number: 7897180Abstract: The present invention relates to the use of a preparation of an active enamel matrix substance, such as an amelogenin, for the manufacture of a pharmaceutical composition for modulating an immune response. The composition can be used in preventing and/or treating a condition or disease in a mammal that is characterised by said mammal presenting an imbalance in its native immune response to an internal and/or external stimuli, i.e. wherein at least a part of said mammal's immune system is stimulated non-discriminatingly, reacts hypersensitively to said immunogen, or fails to react to said stimuli. Said condition can typically either be systemic or local, such as a systemic and/or post-traumatic whole-body inflammation or an autoimmune disease.Type: GrantFiled: October 7, 2009Date of Patent: March 1, 2011Assignee: Institut Straumann AGInventors: Stina Gestrelius, Petter Lyngstadaas
-
Publication number: 20100234298Abstract: Enamel matrix, enamel matrix derivatives and/or enamel matrix proteins or peptides may be used as therapeutic or prophylactic agents for inducing programmed cell death (apoptosis), in particular in the treatment or prevention of cancer or malignant or benign neoplasms.Type: ApplicationFiled: April 14, 2010Publication date: September 16, 2010Applicant: INSTITUT STRAUMANN AGInventors: Lars Hammarstrom, Stale Petter Lyngstadaas, Stina Gestrelius
-
Publication number: 20100093632Abstract: The present invention relates to the use of a preparation of an active enamel matrix substance, such as an amelogenin, for the manufacture of a pharmaceutical composition for modulating an immune response. The composition can be used in preventing and/or treating a condition or disease in a mammal that is characterised by said mammal presenting an imbalance in its native immune response to an internal and/or external stimuli, i.e. wherein at least a part of said mammal's immune system is stimulated non-discriminatingly, reacts hypersensitively to said immunogen, or fails to react to said stimuli. Said condition can typically either be systemic or local, such as a systemic and/or post-traumatic whole-body inflammation or an autoimmune disease.Type: ApplicationFiled: October 7, 2009Publication date: April 15, 2010Applicant: Institut Straumann AGInventors: Stina Gestrelius, Petter Lyngstadaas
-
Patent number: 7608284Abstract: The present invention relates to the use of a preparation of an active enamel matrix substance, such as an amelogenin, for the manufacture of a pharmaceutical composition for modulating an immune response. The composition can be used in preventing and/or treating a condition or disease in a mammal that is characterised by said mammal presenting an imbalance in its native immune response to an internal and/or external stimuli, i.e. wherein at least a part of said mammal's immune system is stimulated non-discriminatingly, reacts hypersensitively to said immunogen, or fails to react to said stimuli. Said condition can typically either be systemic or local, such as a systemic and/or post-traumatic whole-body inflammation or an autoimmune disease.Type: GrantFiled: September 12, 2002Date of Patent: October 27, 2009Assignee: Institut Straumann AGInventors: Stina Gestrelius, Petter Lyngstadaas
-
Patent number: 7304030Abstract: The present invention relates to the surprising finding that enamel matrix, enamel matrix derivatives and/or enamel matrix proteins induce dentin regeneration. The invention thus relates to the use of a preparation of an active enamel substance for the preparation of a pharmaceutical composition for the formation or regeneration of dentin following dental procedures involving exposure of vital dental pulp tissue. In another aspect, the invention relates to a method of promoting the formation or regeneration of dentin following dental procedures involving exposure of vital dental pulp tissue, the method comprising applying an effective amount of an active enamel substance on exposed vital dental pulp tissue after dental procedures.Type: GrantFiled: June 19, 2001Date of Patent: December 4, 2007Assignee: Biora ABInventors: Ståle Petter Lyngstadaas, Stina Gestrelius
-
Patent number: 7294352Abstract: Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection or inflammation.Type: GrantFiled: October 30, 2003Date of Patent: November 13, 2007Assignee: Biora BioEx ABInventors: Stina Gestrelius, Lars Hammarström, Petter Lyngstadaas, Christer Andersson, Ivan Slaby, Tomas Hammargren
-
Patent number: 7033611Abstract: The present invention relates to the use of enamel matrix, enamel matrix derivatives and/or enamel matrix proteins as therapeutic and/or cosmetic agents. These substances are used for the manufacture of a pharmaceutical and/or cosmetic composition for actively inducing, guiding and/or stimulating connective tissue growth and thus to prevent connective tissue scarring and/or contraction in a wound cavity and/or tissue defect that is characterized by a substantial loss of tissue. The invention comprises, in particular, the use of active enamel substances for guided connective soft tissue growth and resistance to contraction in deep cavity shaped wounds following loss or removal of significant volumes of tissue, such as e.g., after surgical removal of a tumor and especially in combination with radiation therapy.Type: GrantFiled: February 21, 2002Date of Patent: April 25, 2006Assignee: Biora Bioex ABInventors: Ståle Petter Lyngstadaas, Stina Gestrelius
-
Patent number: 6979670Abstract: Enamel matrix, enamel matrix derivatives and/or enamel matrix proteins are used in the preparation of a pharmaceutical composition for promoting the take of a graft, e.g. in soft tissue such as skin or mucosa or mineralized tissue such as bone.Type: GrantFiled: March 9, 2000Date of Patent: December 27, 2005Assignee: Biora BioEx ABInventors: Ståle Petter Lyngstadaas, STina Gestrelius
-
Publication number: 20050271604Abstract: Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection or inflammation.Type: ApplicationFiled: October 30, 2003Publication date: December 8, 2005Inventors: Stina Gestrelius, Lars Hammarstrom, Petter Lyngstadaas, Christer Andersson, Ivan Slaby, Tomas Hammargren
-
Publication number: 20050214231Abstract: The present invention relates to the surprising finding that enamel matrix, enamel matrix derivatives and/or enamel matrix proteins induce dentin regeneration. The invention thus relates to the use of a preparation of an active enamel substance for the preparation of a pharmaceutical composition for the formation or regeneration of dentin following dental procedures involving exposure of vital dental pulp tissue. In another aspect, the invention relates to a method of promoting the formation or regeneration of dentin following dental procedures involving exposure of vital dental pulp tissue, the method comprising applying an effective amount of an active enamel substance on exposed vital dental pulp tissue after dental procedures.Type: ApplicationFiled: June 19, 2001Publication date: September 29, 2005Inventors: Stale Lyngstadaas, Stina Gestrelius
-
Publication number: 20050043216Abstract: Enamel matrix, enamel matrix derivatives and/or enamel matrix proteins or peptides may be used as therapeutic or prophylactic agents for inducing programmed cell death (apoptosis), in particular in the treatment or prevention of cancer or malignant or benign neoplasms.Type: ApplicationFiled: June 29, 2004Publication date: February 24, 2005Inventors: Lars Hammarstrom, Stale Lyngstadaas, Stina Gestrelius
-
Publication number: 20040072727Abstract: The present invention relates to the use of enamel matrix, enamel matrix derivatives and/or enamel matrix proteins as therapeutic and/or cosmetic agents. Said substances are sued for the manufacture of a pharmaceutical and/or cosmetic composition for actively inducing guiding and/or stimulating connective tissue growth and thus to prevent connective tissue scaring and/or contraction in a wound cavity and/or tissue defect that is characterised by a substantial loss of tissue. Comprised in the invention is in particular the use of active enamel substances for guided connective soft tissue growth and resistance to contraction in deep cavity shaped wounds following loss or removal of significant volumes of tissue, such as e.g. after surgical removal of a tumour and especially in combination with radiation therapy.Type: ApplicationFiled: August 22, 2003Publication date: April 15, 2004Inventors: Stale Petter Lyngstadaas, Stina Gestrelius
-
Patent number: 6720009Abstract: Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection or inflammation.Type: GrantFiled: May 28, 2002Date of Patent: April 13, 2004Assignee: Biora BioEx ABInventors: Stina Gestrelius, Lars Hammarström, Petter Lyngstadaas, Christer Andersson, Ivan Slaby, Tomas Hammargren
-
Publication number: 20030096740Abstract: Enamel matrix, enamel matrix derivatives and/or enamel matrix proteins or peptides may be used as therapeutic or prophylactic agents for inducing programmed cell death (apoptosis), in particular in the treatment or prevention of cancer or malignant or benign neoplasms.Type: ApplicationFiled: March 9, 2000Publication date: May 22, 2003Inventors: Lars Hammarstrom, Stale Petter Lyngstadaas, Stina Gestrelius
-
Publication number: 20030077291Abstract: The present invention relates to the use of a preparation of an active enamel matrix substance, such as an amelogenin, for the manufacture of a pharmaceutical composition for modulating an immune response. The composition can be used in preventing and/or treating a condition or disease in a mammal that is characterised by said mammal presenting an imbalance in its native immune response to an internal and/or external stimuli, i.e. wherein at least a part of said mammal's immune system is stimulated non-discriminatingly, reacts hypersensitively to said immunogen, or fails to react to said stimuli. Said condition can typically either be systemic or local, such as a systemic and/or post-traumatic whole-body inflammation or an autoimmune disease.Type: ApplicationFiled: September 12, 2002Publication date: April 24, 2003Inventors: Stina Gestrelius, Petter Lyngstadaas
-
Publication number: 20030064927Abstract: Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection or inflammation.Type: ApplicationFiled: May 28, 2002Publication date: April 3, 2003Applicant: Biora BioEx ABInventors: Stina Gestrelius, Lars Hammarstrom, Petter Lyngstadaas, Christer Andersson, Ivan Slaby, Tomas Hammargren
-
Patent number: 6503539Abstract: Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection or inflammation.Type: GrantFiled: February 26, 1999Date of Patent: January 7, 2003Assignee: Biora BioEx ABInventors: Stina Gestrelius, Lars Hammarström, Petter Lyngstadaas, Christer Andersson, Ivan Slaby, Tomas Hammargren
-
Publication number: 20020169105Abstract: Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection or inflammation.Type: ApplicationFiled: February 26, 1999Publication date: November 14, 2002Inventors: STINA GESTRELIUS, LARS HAMMARSTROM, PETTER LYNGSTADAAS, CHRISTER ANDERSSON, IVAN SLABY, TOMAS HAMMARGREN